We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Universal Health Services
UHS
$10.4B
| $30.9K | ﹤0.01% |
196
+2
| +1% | +$279 |
|
1727
Provident Financial Services
PFS
$3.04B
| $30.7K | ﹤0.01% |
1,880
-8
| -0.4% | -$136 |
|
1728
Unitil
UTL
$951M
| $30.3K | ﹤0.01% |
598
+322
| +117% | +$17.9K |
|
1729
Edgewell Personal Care
EPC
$1.23B
| $29.9K | ﹤0.01% |
723
-558
| -44% | -$23.8K |
|
1730
Regency Centers
REG
$13.6B
| $29.8K | ﹤0.01% |
482
-113
| -19% | -$6.72K |
|
1731
PTC Therapeutics
PTCT
$5.48B
| $29.8K | ﹤0.01% |
732
-7,265
| -91% | -$355K |
|
1732
Sutro Biopharma
STRO
$275M
| $29.7K | ﹤0.01% |
639
-4
| -0.6% | -$199 |
|
1733
John B. Sanfilippo & Son
JBSS
$799M
| $29.4K | ﹤0.01% |
251
-195
| -44% | -$21.9K |
|
1734
American Public Education
APEI
$819M
| $29.4K | ﹤0.01% |
6,208
+2,190
| +55% | +$11.9K |
|
1735
Huntington Ingalls Industries
HII
$11B
| $29.1K | ﹤0.01% |
128
-518
| -80% | -$108K |
|
1736
News Corp Class A
NWSA
$16.3B
| $28.9K | ﹤0.01% |
1,481
+1
| +0.1% | +$18 |
|
1737
APA Corp
APA
$16.6B
| $28.7K | ﹤0.01% |
840
| – | – |
|
1738
Innovative Industrial Properties
IIPR
$1.56B
| $28.3K | ﹤0.01% |
388
-8,791
| -96% | -$619K |
|
1739
Vir Biotechnology
VIR
$1.77B
| $28K | ﹤0.01% |
1,140
-946
| -45% | -$23.8K |
|
1740
Cushman & Wakefield Ltd
CWK
$2.94B
| $27.4K | ﹤0.01% |
3,345
-67,981
| -95% | -$591K |
|
1741
SkinHealth Systems
SKIN
$87.8M
| $27.1K | ﹤0.01% |
3,243
-3,298
| -50% | -$34.3K |
|
1742
Monolithic Power Systems
MPWR
$56.1B
| $26.5K | ﹤0.01% |
49
-16
| -25% | -$7.6K |
|
1743
Enova International
ENVA
$4.32B
| $26.4K | ﹤0.01% |
497
-434
| -47% | -$20.5K |
|
1744
Black Diamond Therapeutics
BDTX
$113M
| $25.5K | ﹤0.01% |
5,046
-8,139
| -62% | -$16.6K |
|
1745
Patterson-UTI
PTEN
$4.85B
| $24.9K | ﹤0.01% |
+2,080
| New | +$23.5K |
|
1746
Terreno Realty
TRNO
$7.11B
| $23.9K | ﹤0.01% |
398
+10
| +3% | +$610 |
|
1747
American Eagle Outfitters
AEO
$2.48B
| $23K | ﹤0.01% |
1,946
-367
| -16% | -$4.58K |
|
1748
DoubleVerify
DV
$2.09B
| $22.9K | ﹤0.01% |
588
+122
| +26% | +$3.94K |
|
1749
Fastly Inc
FSLY
$3.87B
| $22.9K | ﹤0.01% |
1,451
+113
| +8% | +$1.73K |
|
1750
First Merchants
FRME
$2.62B
| $22.3K | ﹤0.01% |
790
-403
| -34% | -$11.4K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.